ProQR Therapeutics (PRQR) Common Equity (2021 - 2025)

ProQR Therapeutics (PRQR) has disclosed Common Equity for 5 consecutive years, with $57.5 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 39.27% to $57.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $57.5 million through Dec 2025, down 39.27% year-over-year, with the annual reading at $57.5 million for FY2025, 39.27% down from the prior year.
  • Common Equity hit $57.5 million in Q4 2025 for ProQR Therapeutics, down from $94.6 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $130.5 million in Q4 2021 to a low of $44.5 million in Q4 2023.
  • Historically, Common Equity has averaged $79.0 million across 5 years, with a median of $68.0 million in 2022.
  • Biggest five-year swings in Common Equity: crashed 47.88% in 2022 and later surged 112.5% in 2024.
  • Year by year, Common Equity stood at $130.5 million in 2021, then plummeted by 47.88% to $68.0 million in 2022, then tumbled by 34.54% to $44.5 million in 2023, then surged by 112.5% to $94.6 million in 2024, then tumbled by 39.27% to $57.5 million in 2025.
  • Business Quant data shows Common Equity for PRQR at $57.5 million in Q4 2025, $94.6 million in Q4 2024, and $44.5 million in Q4 2023.